Research Studies
X-Linked Hypophosphatemia
- A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia (XLH)
- PI: Dr. Clemens Bergwitz
- Study Details | NCT06525636 | A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia | ClinicalTrials.gov
- Industry-sponsored use of a medication similar to Burosumab/ Crysvita, as a long-acting injection for treatment of XLH
- A Prospective Observational Cohort Study of XLH in Adults
- PI: Dr. Peter Tebben
- Industry-sponsored disease monitoring program evaluating clinical, laboratory, and imaging data in adults with XLH
- XLH Disease Monitoring Program
- Principal Investigator (PI): Dr. Thomas Carpenter
- o This ongoing ten year in-person program is a detailed and systematic industry-sponsored international study of the natural history and clinical course of XLH. The study incorporates children and adults undergoing various (or no) therapies, and collects clinical, laboratory and imaging data.
- Closed to enrollment
- Study Details | NCT03651505 | X-linked Hypophosphatemia Disease Monitoring Program | ClinicalTrials.gov
Osteogenesis Imperfecta
- Osteogenesis Imperfecta (OI) Trial of AGA2115 for Adults with Genetic Variants of COL1A1 and/or COL1A2
- PI: Dr. Peter Tebben
- Study Details | NCT07062588 | Osteogenesis Imperfecta Trial of AGA2115 for Adults With COL1A1 and/or COL1A2 Genetic Variations (IDUN) | ClinicalTrials.gov
- Industry-sponsored use of AGA2115, a humanized bispecific antibody that neutralizes DKK1 and sclerostin, as injections for the treatment of OI in adults
- Setrusumab vs Placebo for OI
- PI: Dr. Thomas Carpenter
- Closed to enrollment
- Study Details | NCT05125809 | Setrusumab vs Placebo for Osteogenesis Imperfecta | ClinicalTrials.gov
- Industry-sponsored use of setrusumab, an anti-sclerostin antibody, as monthly infusions for the treatment of OI in 5–25-year-olds
- Setrusumab vs Bisphosphonates in Pediatric Subjects with OI
- PI: Dr. Thomas Carpenter o Closed to enrollment
- Study Details | NCT05768854 | Setrusumab vs Bisphosphonates in Pediatric Subjects with Osteogenesis Imperfecta | ClinicalTrials.gov
- This industry-sponsored study compares setrusumab, an anti-sclerostin antibody, with bisphosphonate infusions for the treatment of OI in 2-7 year-olds children
Hypoparathyroidism
- Evaluating Encaleret in Pediatric Participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- PI: Dr. Peter Tebben
- Study Details | NCT07080385 | Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1) | ClinicalTrials.gov
- Industry-sponsored use of encaleret, a negative allosteric modulator of the Calcium-Sensing Receptor, as a daily oral therapy for ADH1 in children up to 17 years of age.
- Natural History of Hypoparathyroidism
- PI: Dr. Thomas Carpenter
- This industry-sponsored program studies the natural history and clinical course of individuals affected with hypoparathyroidism and autosomal dominant hypocalcemia.
- Closed to enrollment
- Study Details | NCT01922440 | A Registry for Participants with Chronic Hypoparathyroidism | ClinicalTrials.gov
Tumor-Induced Osteomalacia
- Tumor-Induced Osteomalacia (TIO) Disease Monitoring Program
- PI: Dr. Thomas Carpenter
- This ongoing program is a long-term, detailed and systematic industry-sponsored study of the natural history and clinical course of TIO
- Closed to enrollment
- Study Details | NCT04783428 | Tumor-induced Osteomalacia Disease Monitoring Program | ClinicalTrials.gov